Nipah virus (NiV) is a highly pathogenic zoonotic RNA virus first identified in Malaysia in 1998. It has caused several regional outbreaks, primarily affecting the central nervous and respiratory systems, with case fatality rates ranging from 40% to 75%. The World Health Organization (WHO) currently lists NiV as a "priority pathogen," as there are no approved vaccines or specific antiviral drugs. Of the two main strains—Malaysian (NiV-M) and Bangladesh (NiV-B)—the latter is considered more virulent. The recent West Bengal outbreak has been confirmed as the Bangladesh strain.
Sino Biological has successfully developed NiV F and G proteins, along with detection antibodies, which serve as critical tools for NiV research. Furthermore, the N protein, pre-F trimer, and post-F trimer proteins will be available soon, providing comprehensive support for the development of NiV vaccines and diagnostic reagents. To complement these standard proteins, Sino Biological also offers ProPure™ endotoxin-free (ET-free) versions of NiV G and F proteins, specifically designed for vaccine research where immunogen purity and endotoxin control are critical.
